Roche shows Tecentriq/Avastin combo helps liver cancer patients live longer

With an eye on a swelling Chinese market, Roche unveiled Phase III data showing a combination of Tecentriq, its immunotherapy, and Avastin could help patients with the most common form of liver cancer live longer than under the standard treatment, Bayer’s Nexavar.